bioRxivBioengineeringPreprint
A Multivalent Peptide-Polymer Conjugate Material Mimics STING to Therapeutically Activate Innate Immune Signaling
Justin A. KaskowiD, Julia TreeseiD, Anita Gaenko, Victoria F. GomerdingeriD, Zhi Kai Tio, Margaret M. BillingsleyiD, Aidan KindoppiD, Paula Therese HammondiD
Abstract
Stimulator of interferon genes (STING) is a promising therapeutic target for cancer immunotherapy, but agonists are often rendered ineffective by the loss of STING expression in cancer cells. Here we engineer a multivalent peptide-polymer conjugate material that can easily be delivered to the cytosol, where it mimics key protein interactions from the missing STING protein to directly activate downstream innate immune signaling. While previously developed STING mimicking therapeutics use nearly the full STING protein, this material contains only a 39 amino acid peptide from the STING C-terminal tail that includes interaction motifs for downstream kinase TBK1 and transcription factor IRF3. Conjugation of multiple peptide copies to a negatively charged polymer backbone mimics the multivalent protein-protein interactions of the oligomerized STING signaling complex, activating TBK1 and IRF3 as well as the transcription of downstream genes in both STING-proficient and STING-silenced cancer cell lines. We optimize a lipid nanoparticle formulation to deliver this conjugate material intracellularly, allowing for its application as an immunotherapy for ovarian cancer. Treatment with the STING mimicking conjugate material promoted the production of type I interferons, repolarization of myeloid cells to an anti-tumor phenotype, and recruitment of T cells to tumors in mice. This treatment ultimately led to tumor regression and extended survival in multiple mouse models of metastatic ovarian cancer. Overall, this work highlights the potential of peptide-polymer conjugate mimics of STING to therapeutically activate innate immune signaling.
- organism: mouse
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy
Taylor L. Sheehy, Alexander J. Kwiatkowski, … John T. Wilson·ACS Central SciencePeer-reviewed·Aug 20, 2024
- Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approach
W. Liu, M.-G. Alameh, … J. You·bioRxiv·Jan 8, 2022
- STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity
- Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation
Emily F. Higgs, Thomas Frank Gajewski·bioRxiv·Apr 8, 2024
- Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapy
Malin Pedersen, Lisa C. Hubbard, … Kevin J Harrington·bioRxiv·Mar 25, 2026
- Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects
L. D. Towner, L. N. Dahal, … S. A. Beers·bioRxiv·Jan 4, 2023